S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Game-Changing Cancer Tech Nears FDA Completion (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
The Strategic Gold Play You Haven't Heard About (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Game-Changing Cancer Tech Nears FDA Completion (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
The Strategic Gold Play You Haven't Heard About (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Game-Changing Cancer Tech Nears FDA Completion (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
The Strategic Gold Play You Haven't Heard About (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Game-Changing Cancer Tech Nears FDA Completion (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
The Strategic Gold Play You Haven't Heard About (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support

Catalent (CTLT) Stock Price, News & Analysis

$57.34
-0.60 (-1.04%)
(As of 02/29/2024 ET)
Today's Range
$57.25
$58.20
50-Day Range
$42.56
$59.82
52-Week Range
$31.45
$74.49
Volume
3.63 million shs
Average Volume
4.39 million shs
Market Capitalization
$10.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.46

Catalent MarketRank™ Stock Analysis

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
8.5% Downside
$52.46 Price Target
Short Interest
Healthy
4.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.93mentions of Catalent in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
157.69%
From $0.52 to $1.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.56 out of 5 stars

Medical Sector

268th out of 957 stocks

Pharmaceutical Preparations Industry

121st out of 439 stocks


CTLT stock logo

About Catalent Stock (NYSE:CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CTLT Stock Price History

CTLT Stock News Headlines

S&P 500's surge to new highs: Bull trap hiding in plain sight? (CTLT)
Nvidia and Meta lead the S&P 500 rally, but there's cause for concern about a potential bull trap amid market volatility and a pivot to stable dividend payers.
Can financial, healthcare, energy stocks rise as rates stay high? (CTLT)
Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
In-Depth Examination Of 5 Analyst Recommendations For Catalent
Catalent gains after filing 10-Q
Catalent Posts Wider-than-expected Q2 Loss; Revenues Down
Catalent: Fiscal Q2 Earnings Snapshot
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
Catalent - Novo Holdings Merger: Attractive Spread
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
3/01/2024
Next Earnings (Estimated)
6/10/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
17,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.46
High Stock Price Target
$63.50
Low Stock Price Target
$42.00
Potential Upside/Downside
-8.5%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
13 Analysts

Profitability

Net Income
$-256,000,000.00
Pretax Margin
-34.91%

Debt

Sales & Book Value

Annual Sales
$4.28 billion
Cash Flow
$3.20 per share
Book Value
$20.40 per share

Miscellaneous

Free Float
180,178,000
Market Cap
$10.36 billion
Optionable
Optionable
Beta
1.20
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report














CTLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price target for 2024?

13 Wall Street analysts have issued twelve-month target prices for Catalent's stock. Their CTLT share price targets range from $42.00 to $63.50. On average, they predict the company's stock price to reach $52.46 in the next year. This suggests that the stock has a possible downside of 8.5%.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2024?

Catalent's stock was trading at $44.93 at the beginning of 2024. Since then, CTLT stock has increased by 27.6% and is now trading at $57.34.
View the best growth stocks for 2024 here
.

Are investors shorting Catalent?

Catalent saw a decline in short interest in February. As of February 15th, there was short interest totaling 7,450,000 shares, a decline of 33.1% from the January 31st total of 11,130,000 shares. Based on an average trading volume of 2,590,000 shares, the days-to-cover ratio is currently 2.9 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024.
View our CTLT earnings forecast
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its earnings results on Friday, February, 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.22. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative trailing twelve-month return on equity of 2.43% and a negative net margin of 29.91%. The business's revenue was down 10.2% on a year-over-year basis. During the same period last year, the company earned $0.62 earnings per share.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2024 earnings guidance on Monday, December, 11th. The company provided earnings per share guidance of 0.620-0.960 for the period, compared to the consensus EPS estimate of 0.810. The company issued revenue guidance of $4.3 billion-$4.5 billion, compared to the consensus revenue estimate of $4.4 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Who are Catalent's major shareholders?

Catalent's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.17%), Capital World Investors (10.56%), Nomura Holdings Inc. (6.36%), Price T Rowe Associates Inc. MD (4.67%), Veritas Asset Management LLP (3.58%) and Cadian Capital Management LP (3.36%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano and Thomas W Hawkeswood.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CTLT) was last updated on 3/1/2024 by MarketBeat.com Staff